Evidence map›Paper›PMID 33704772›Full record

ArticleBiotechnology and bioengineering2021

Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines.

Sowmya Rajendran, Sowmya Balasubramanian, Lynn Webster, Maggie Lee, Divya Vavilala, Nicolay Kulikov, Jessica Choi, Calvin Tang, Molly Hunter, Rebecca Wang and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology and bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Recombinant CHO Cell Pool Generation Using PiggyBac Transposon System.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Sowmya RajendranCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Sowmya BalasubramanianCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Lynn WebsterCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Maggie LeeCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Divya VavilalaCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Nicolay KulikovCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Jessica ChoiCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Calvin TangCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Molly HunterCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Rebecca WangCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Harpreet KaurCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Surya KarunakaranCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Varsha SitaramanCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Jeremy MinshullCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Ferenc BoldogCell Line Development, Protein Purification and Protein Analytical Departments of ATUM, Inc., Newark, California, USA.
Protein Express (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of highly productive, genetically stable manufacturing cell lines is on the critical path to IND filing for protein-based biologic drugs. Here, we describe the Leap-In Transposase® platform, a novel transposon-based mammalian (e.g., Chinese hamster ovary) cell line development system that produces high-titer stable pools with productivity and product quality attributes that are highly comparable to clones that are subsequently derived therefrom. The productivity distributions of clones are strongly biased toward high producers, and genetic and expression stability is consistently high. By avoiding the poor integration rates, concatemer formation, detrimental transgene recombination, low average expression level, unpredictable product quality, and inconsistent genetic stability characteristic of nonhomologous recombination methods, Leap-In provides several opportunities to de-risk programs early and reduce timelines and resources.

Indexed as

Cell LineDNA Transposable ElementsTransgenesTransposasesAnimalsBioengineeringBiological ProductsCHO CellsClone CellsCricetulusHumansMammalsMicePromoter Regions, GeneticBiological ProductsDNA Transposable ElementsTransposasescell line developmentintegrationLeap-In transposasestable poolstransposasetransposon

Identifiers

PMID33704772
PMCPMC8252637
OpenAlexW3133798478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.